Immuron Limited
IMRNAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| H.C. Wainwright | maintain | Buy | Oct 18, 2017 |
Earnings History
Next report: Feb 19, 2027 · EPS est. $-0.01| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 28, 2026 | $-0.17 | $-0.00 | $2.5M | $2.7M |
| Feb 25, 2026 | $-0.20 | $-0.01 | $3.0M | $2.9M |
| Aug 28, 2025 | $-0.01 | $-0.01 | $2.1M | $2.0M |
| Feb 28, 2025 | $-0.27 | $-0.01 | $2.5M | $1.7M |
| Aug 30, 2024 | $-0.01 | — | $1.7M | $2.4M |
| Feb 28, 2024 | $-0.25 | — | $1.6M | — |
| Aug 30, 2023 | $-0.11 | — | $405.5K | — |
| Feb 28, 2023 | $-0.12 | — | $199.4K | — |
News
Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) Q1 sales up 12% on prior quarter Canada Q1 sales AUD$0.1 million up 286% on prior comparative period (pcp) Q1 sales up 63% on prior quarter USA Q1 sales AUD$0.3 million down 19% on prior comparative period (pcp) Q1 sales down 24% on prior quarter MELBOURNE, Australia, Oct. 27, 2026 (GLOBE …
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm – 4:55pm U.S. Eastern Time).
MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controlled study to evaluate once-daily oral Travelan for the prevention of Travellers' Diarrhoea," describes c…
Immuron (NASDAQ: IMRN - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling 115,685 shares, an increase of 240.2% from the August 31st total of 34,009 shares. Approximately 1.5% of the company's stock are sold short. Based on an average trading
Shares of Immuron (NASDAQ: IMRN - Get Free Report) dropped 2.5% on Friday. The company traded as low as $1.16 and last traded at $1.16. 43,882 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 6,531,659 shares. The stock had previously closed at $1.19. Analysts Set New Price Targets
Shares of Immuron Limited (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in the United States. Here's what investors need to know.
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Immuron (NASDAQ: IMRN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Analyst Recommendations This is a breakdown of recent
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.